DK1734989T3 - Ny anvendelse af antisekretorisk faktor-protein - Google Patents
Ny anvendelse af antisekretorisk faktor-proteinInfo
- Publication number
- DK1734989T3 DK1734989T3 DK04775470.0T DK04775470T DK1734989T3 DK 1734989 T3 DK1734989 T3 DK 1734989T3 DK 04775470 T DK04775470 T DK 04775470T DK 1734989 T3 DK1734989 T3 DK 1734989T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- condition
- stem cell
- disease
- new use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0322645.3A GB0322645D0 (en) | 2003-09-26 | 2003-09-26 | Use of antisecretory factor peptides |
PCT/SE2004/001369 WO2005030246A1 (en) | 2003-09-26 | 2004-09-24 | Novel use of antisecretory factor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1734989T3 true DK1734989T3 (da) | 2012-07-09 |
Family
ID=29286947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04775470.0T DK1734989T3 (da) | 2003-09-26 | 2004-09-24 | Ny anvendelse af antisekretorisk faktor-protein |
Country Status (18)
Country | Link |
---|---|
US (2) | US20070009575A1 (da) |
EP (1) | EP1734989B1 (da) |
JP (1) | JP4943847B2 (da) |
KR (1) | KR101159858B1 (da) |
CN (2) | CN1856320A (da) |
AT (1) | ATE550030T1 (da) |
AU (1) | AU2004275682B2 (da) |
BR (1) | BRPI0414793A (da) |
CA (1) | CA2537335C (da) |
DK (1) | DK1734989T3 (da) |
ES (1) | ES2384385T3 (da) |
GB (1) | GB0322645D0 (da) |
IL (1) | IL174464A (da) |
NO (1) | NO340187B1 (da) |
NZ (1) | NZ545661A (da) |
RU (1) | RU2416426C2 (da) |
WO (1) | WO2005030246A1 (da) |
ZA (1) | ZA200601807B (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007126364A2 (en) * | 2006-04-27 | 2007-11-08 | Lantmännen As-Faktor Ab | Use of antisecretory factors for treating intraocular hypertension |
AU2012201165B2 (en) * | 2006-04-27 | 2013-12-19 | Lantmannen As-Faktor Ab | New approach to treat intraocular hypertension |
MX2008013777A (es) * | 2006-04-27 | 2009-02-03 | Lantmaennen As Faktor Ab | Usos medicos adicionales de la proteina antisecretora. |
RU2465914C2 (ru) * | 2006-04-27 | 2012-11-10 | Лантменнен Ас-Фактор | Новый подход к лечению компартмент-синдрома |
US9962424B2 (en) | 2007-04-27 | 2018-05-08 | Lantmännen As-Faktor Ab | Use of antisecretory factors (AF) for optimizing cellular uptake |
WO2010093324A1 (en) * | 2009-02-11 | 2010-08-19 | Lantmännen As-Faktor Ab | Use of antisecretory factors (af) for optimizing cellular uptake |
ITMI20120008A1 (it) * | 2012-01-04 | 2013-07-05 | Biava Maura | Composizioni ad attività anti-neurodegenerativa |
US9738553B2 (en) * | 2012-03-16 | 2017-08-22 | Aquatech International, Llc | Process for purification of produced water |
AU2013263346B2 (en) * | 2012-05-18 | 2018-08-23 | The General Hospital Corporation | Methods and compositions for treating amyloid deposits |
CA3036216A1 (en) * | 2012-12-20 | 2014-06-26 | Lantmannen As-Faktor Ab | Use of antisecretory factor (af) in glioblastoma treatment |
MX2018000069A (es) | 2015-07-10 | 2018-03-16 | Lantmaennen As Faktor Ab | Proceso para producir yema de huevo con alto contenido de factor antisecretor 16. |
AU2017299131B2 (en) * | 2016-07-18 | 2020-05-21 | Lantmännen As-Faktor Ab | Antisecretory Factor 17 |
JP7217760B2 (ja) | 2018-06-28 | 2023-02-03 | ラントメネン・メディカル・アーベー | 急性呼吸不全の治療および/または予防の使用のための抗分泌因子 |
WO2020065091A1 (en) | 2018-09-28 | 2020-04-02 | Lantmännen Functional Foods Ab | A consumable product comprising malted wheat |
CN112770643A (zh) | 2018-09-28 | 2021-05-07 | 兰特门内保健食品公司 | 包含麦芽化脱壳燕麦的可消耗产品 |
EP4125984A1 (en) * | 2020-03-26 | 2023-02-08 | Lantmännen Functional Foods AB | A consumable product comprising malted cereals for promoting recovery at physical activity |
CN112006035B (zh) * | 2020-07-24 | 2021-07-30 | 江西新龙生物科技股份有限公司 | 用于防治植物病害的微生物源杀菌剂及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7566455B1 (en) * | 1995-06-07 | 2009-07-28 | Gpc Biotech, Inc. | E6AP-binding proteins |
SE508609C2 (sv) * | 1995-08-24 | 1998-10-19 | Rural Patent Svenska Ab | Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning |
WO1997027296A1 (en) * | 1996-01-26 | 1997-07-31 | Hsc Research And Development Limited Partnership | Nucleic acids and proteins related to alzheimer's disease, and uses therefor |
SE513496C2 (sv) * | 1998-12-17 | 2000-09-18 | Rural Patent Svenska Ab | NASP-berikad äggula samt dess användning |
EA200100264A1 (ru) * | 1999-06-21 | 2001-10-22 | Филадельфия Хеалс Энд Эдьюкейшн Корпорейшн | Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly |
EP1350847A4 (en) * | 2001-01-09 | 2005-12-28 | Inst Of Gene And Brain Science | HUMAN GLIOMANTIGEN AND METHOD FOR THE PRODUCTION THEREOF |
AU2003205353A1 (en) * | 2002-01-25 | 2003-09-02 | Incyte Genomics, Inc. | Protein modification and maintenance molecules |
-
2003
- 2003-09-26 GB GBGB0322645.3A patent/GB0322645D0/en not_active Ceased
-
2004
- 2004-09-24 US US10/573,601 patent/US20070009575A1/en not_active Abandoned
- 2004-09-24 DK DK04775470.0T patent/DK1734989T3/da active
- 2004-09-24 CN CNA2004800278276A patent/CN1856320A/zh active Pending
- 2004-09-24 RU RU2006114030/15A patent/RU2416426C2/ru active
- 2004-09-24 BR BRPI0414793-6A patent/BRPI0414793A/pt not_active Application Discontinuation
- 2004-09-24 AU AU2004275682A patent/AU2004275682B2/en not_active Ceased
- 2004-09-24 WO PCT/SE2004/001369 patent/WO2005030246A1/en active Application Filing
- 2004-09-24 NZ NZ545661A patent/NZ545661A/en not_active IP Right Cessation
- 2004-09-24 CA CA2537335A patent/CA2537335C/en not_active Expired - Fee Related
- 2004-09-24 CN CN201210570082.4A patent/CN103028110B/zh not_active Expired - Fee Related
- 2004-09-24 ZA ZA200601807A patent/ZA200601807B/en unknown
- 2004-09-24 AT AT04775470T patent/ATE550030T1/de active
- 2004-09-24 ES ES04775470T patent/ES2384385T3/es active Active
- 2004-09-24 KR KR1020067005982A patent/KR101159858B1/ko active IP Right Grant
- 2004-09-24 JP JP2006527946A patent/JP4943847B2/ja not_active Expired - Fee Related
- 2004-09-24 EP EP04775470A patent/EP1734989B1/en active Active
-
2006
- 2006-02-24 NO NO20060901A patent/NO340187B1/no not_active IP Right Cessation
- 2006-03-21 IL IL174464A patent/IL174464A/en active IP Right Grant
-
2010
- 2010-02-26 US US12/659,142 patent/US8748367B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR101159858B1 (ko) | 2012-06-25 |
KR20060097718A (ko) | 2006-09-14 |
JP4943847B2 (ja) | 2012-05-30 |
ZA200601807B (en) | 2007-06-27 |
US20100286052A1 (en) | 2010-11-11 |
RU2006114030A (ru) | 2007-11-20 |
IL174464A (en) | 2015-08-31 |
US20070009575A1 (en) | 2007-01-11 |
EP1734989A1 (en) | 2006-12-27 |
JP2007506735A (ja) | 2007-03-22 |
CN1856320A (zh) | 2006-11-01 |
CN103028110B (zh) | 2016-02-17 |
AU2004275682A1 (en) | 2005-04-07 |
EP1734989B1 (en) | 2012-03-21 |
CA2537335C (en) | 2017-12-05 |
ES2384385T3 (es) | 2012-07-04 |
US8748367B2 (en) | 2014-06-10 |
GB0322645D0 (en) | 2003-10-29 |
RU2416426C2 (ru) | 2011-04-20 |
IL174464A0 (en) | 2006-08-01 |
NO20060901L (no) | 2006-06-20 |
ATE550030T1 (de) | 2012-04-15 |
WO2005030246A1 (en) | 2005-04-07 |
AU2004275682B2 (en) | 2010-01-28 |
NZ545661A (en) | 2009-10-30 |
BRPI0414793A (pt) | 2006-11-21 |
CN103028110A (zh) | 2013-04-10 |
CA2537335A1 (en) | 2005-04-07 |
NO340187B1 (no) | 2017-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060901L (no) | Ny anvendelse av antisekretorisk faktor | |
HUP0500477A2 (hu) | Eljárások és készítmények embrionális és felnőttkori őssejtek támogatására stromasejtek alkalmazásával | |
TR200103233T2 (tr) | Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri. | |
WO2002060955A3 (en) | Modified antibodies and methods of use | |
ATE394110T1 (de) | Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems | |
ATE362766T1 (de) | Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen | |
ATE237339T1 (de) | Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen | |
DE60039752D1 (de) | Herstellung tetravalenter antikörper | |
WO2005046570A3 (en) | Human stem cell materials and methods | |
ATE207351T1 (de) | Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden | |
DE602005018683D1 (de) | Herstellung von 1,4-butandiol und/oder 2-methyl 1,3-propandiol | |
ATE321856T1 (de) | Humane rezeptortyrosinkinase | |
DE602005017812D1 (de) | Multipotente blutstammzellen aus der nabelschnur und zellbehandlungsmittel damit zur behandlung der ischämischen krankheit | |
Zhang et al. | Knockout of p53 leads to a significant increase in ALV-J replication | |
DE69013011D1 (de) | Bcrf1-proteine als inhibitoren von interferon-g(g). | |
DE69130679T2 (de) | Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation | |
WO2007070840A3 (en) | Modified and pulsatile release pharmaceutical formulations of escitalopram | |
ATE304021T1 (de) | Lektin-ähnliche domäne von thrombomodulin und therapeutische verwendung davon | |
WO2006119965A3 (en) | Growth factor mutants with altered biological attributes | |
DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
ATE264112T1 (de) | Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus | |
ATE109509T1 (de) | Anticoagulatorisches protein pp4-x, seine herstellung und verwendung. | |
ATE298244T1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen | |
Babaeva et al. | Hemophilia in the city of Novosibirsk and Novosibirsk region: Clinical phenotype, comorbidity | |
DE69916829D1 (de) | Genetisch veränderte fibroblasten und ihre verwendung |